Connect with us

Business

Buy or Sell the mRNA Pioneer?

Published

on

Corning GLW Stock 2026 Outlook: Buy or Sell the AI

NEW YORK — Moderna Inc. (NASDAQ: MRNA) faces a pivotal year in 2026 as the biotechnology company transitions from pandemic-driven revenues toward diversified growth in respiratory vaccines, oncology and rare diseases. With shares trading near $47-51 in early June, analysts maintain a largely neutral to cautious stance amid lingering losses and pipeline dependencies.

Moderna reported first-quarter 2026 revenue of approximately $400 million, representing a significant year-over-year increase driven largely by international markets and strategic partnerships. The company reiterated expectations for up to 10% revenue growth for the full year while projecting year-end cash and investments between $4.5 billion and $5 billion. Despite the top-line improvement, the firm posted a GAAP net loss of $1.3 billion, partly due to a substantial litigation settlement charge.

The core COVID-19 franchise continues to generate revenue through Spikevax and updated formulations, though at lower volumes than peak pandemic years. The RSV vaccine mRESVIA has contributed to the respiratory portfolio, with ongoing Phase 3 studies evaluating combinations and revaccination strategies. Management highlighted strong execution on long-term agreements, particularly in international markets that accounted for roughly 80% of Q1 revenue.

Pipeline progress remains central to the investment thesis. Moderna is advancing multiple mRNA candidates, including personalized cancer vaccines in partnership with Merck, such as mRNA-4157 for melanoma and other indications. Additional programs target flu, norovirus, CMV and rare diseases. Positive Phase 3 data readouts expected later in 2026 could serve as major catalysts if successful.

Advertisement

Analyst consensus leans neutral. Most Wall Street firms rate the stock as Hold, with an average 12-month price target around $35-46, implying limited upside or modest downside from current levels. Price targets range widely from as low as $21 to highs near $69-135 in more optimistic scenarios. Ratings distribution shows a mix of Buy, Hold and Sell, reflecting uncertainty around profitability timelines and clinical risks.

Bullish arguments focus on Moderna’s platform potential. The mRNA technology that powered rapid COVID-19 vaccine development offers broad applicability. Successful commercialization of RSV and combination respiratory vaccines, alongside oncology breakthroughs, could drive a return to sustainable growth. The company maintains a robust cash position to fund research without immediate financing pressure.

Chief Executive Stéphane Bancel and the leadership team have expressed confidence in 2026 as a year of returning to growth. International momentum and pipeline milestones position Moderna to capitalize on its technological edge. Long-term believers see substantial upside if the company delivers on late-stage trials and secures additional approvals.

Risks abound for potential buyers. Moderna continues to operate at a net loss as it invests heavily in R&D and commercialization. Competition in the vaccine space is intensifying, while regulatory and clinical hurdles could delay or derail key programs. Valuation concerns persist despite the post-pandemic reset, with shares still carrying premiums that assume successful execution across multiple modalities.

Advertisement

For sellers or those on the sidelines, near-term visibility remains limited. Quarterly results can swing based on vaccine demand and one-time items. Broader biotech sector sentiment, interest rate environments and geopolitical factors affecting supply chains add volatility. Some analysts recommend waiting for clearer signs of profitability or positive Phase 3 data before increasing exposure.

Investment considerations in 2026 hinge on several factors. Revenue diversification beyond COVID remains critical. The RSV franchise and potential flu-COVID-RSV combinations represent meaningful opportunities in the respiratory market. Oncology programs, particularly the individualized neoantigen approach, carry high risk but potentially transformative rewards if approved.

Management has guided for approximately $4.2 billion in cash costs for the year while targeting break-even progress over time. Strong cash reserves provide a buffer for clinical setbacks or slower commercial ramps. Shareholder returns through buybacks or dividends are not currently emphasized, with focus remaining on pipeline advancement.

Broader market context includes ongoing interest in mRNA platforms amid advancements in personalized medicine. However, investor patience is tested by the timeline from clinical data to commercial success. Moderna’s stock has experienced significant swings, rewarding those with high conviction during periods of positive news while punishing delays or disappointing results.

Advertisement

Analysts highlight the need for disciplined execution. Successful data from multiple programs could catalyze re-rating, while any stumbles might pressure shares further. Institutional ownership and analyst coverage remain active, underscoring the stock’s prominence in the biotech sector.

For growth-oriented investors comfortable with volatility and binary clinical outcomes, selective buying on weakness may appeal. Conservative portfolios might prefer smaller positions or waiting for derisking events. Diversification across biotech or healthcare remains advisable given company-specific risks.

Moderna’s story exemplifies the promise and challenges of innovative biotechnology. From its rapid pandemic response to building a broad mRNA pipeline, the company continues pushing scientific boundaries. As 2026 unfolds, upcoming catalysts in respiratory and oncology programs will likely dictate near-term stock performance.

Patients and healthcare systems stand to benefit if additional mRNA products reach the market, addressing unmet needs in infectious disease, cancer and rare conditions. For shareholders, the path forward requires balancing excitement around the platform with realistic expectations around timelines and profitability.

Advertisement

The coming quarters will test Moderna’s ability to convert its scientific leadership into sustained commercial success. While risks remain elevated, those bullish on mRNA’s long-term potential view current levels as an opportunity for patient capital. Others may opt to monitor progress before committing significant capital.

Ultimately, Moderna represents a high-conviction, high-risk bet on next-generation medicines. Investors should conduct thorough due diligence, consider individual risk tolerance and maintain a long-term perspective as the company navigates its post-COVID evolution.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Bitcoin Steadies Near $64,000 as Crypto Traders Brace for a Pivotal Federal Reserve Rate Decision Today

Published

on

Robinhood logo.

Bitcoin traded at $63,860.26 as of Wednesday afternoon, up a modest $13.14, or roughly 0.02%, as cryptocurrency markets settled into a holding pattern ahead of a Federal Reserve interest rate decision that traders across both traditional and digital asset markets have described as unusually difficult to predict.

Bitcoin opened Wednesday at $63,853.49, up 0.2% from Tuesday’s opening price, before climbing as high as $64,244.18 during the morning session, according to pricing data. The cryptocurrency’s relatively flat overall movement Wednesday followed a volatile stretch earlier in the week, including a sharp pullback Tuesday when bitcoin opened 2.5% lower than the previous day, dropping to around $63,327 as investors broadly reduced exposure to riskier assets ahead of the Fed’s two-day policy meeting.

The Federal Reserve’s rate decision, due later Wednesday, has emerged as the dominant catalyst shaping crypto market sentiment this week. According to data from the CME Group’s FedWatch tool, market participants assigned a 35.8% probability to a rate increase following the meeting’s conclusion, up sharply from 25.7% just a week earlier. Separate estimates cited by CoinDesk showed a somewhat different split, with roughly a 70% probability assigned to rates remaining unchanged and a 30% chance of a surprise quarter-point increase. Some analysts have characterized the meeting as among the hardest Fed decisions to forecast in recent years, given the unusual combination of economic signals policymakers are currently weighing.

Ether, the second-largest cryptocurrency by market value, moved somewhat more sharply than bitcoin during the same period. Ethereum opened Wednesday at $1,919.73, up 1.5% from Tuesday’s opening price, before slipping back to $1,904.82 by mid-morning, according to pricing data. Bitcoin and ether moved in opposite directions for stretches of Wednesday’s session, a divergence that market watchers attributed to renewed airstrikes in the Middle East combined with the approaching Fed announcement, both of which have added competing sources of uncertainty for crypto investors this week.

Advertisement

Broader cryptocurrency market data showed modest overall improvement heading into Wednesday. The total global cryptocurrency market capitalization rose 0.4% to reach approximately $2.28 trillion, recovering from a 1.6% decline recorded the previous day, according to data from CoinMarketCap. Bitcoin’s dominance within the broader crypto market held steady at approximately 56.3%, while ether accounted for roughly 10.2% of total market value. Despite the modest recovery in headline prices, a widely tracked measure of investor sentiment, the Fear and Greed Index, remained in “fear” territory at a reading of 28 to 29, reflecting continued caution among traders even as prices stabilized somewhat.

Institutional flows into bitcoin exchange-traded funds showed signs of softening in recent sessions. Spot bitcoin ETFs recorded a net outflow of $11.6 million on July 27, ending a streak of seven consecutive sessions of net inflows, with asset managers BlackRock and Fidelity leading the pullback, according to data on ETF flows. Even so, some corporate treasury activity continued during the same window, with Hyperscale Data disclosing a bitcoin treasury holding of 1,106 bitcoin, valued at approximately $71.7 million, as of July 28, signaling that at least some institutional accumulation of the cryptocurrency has continued despite broader market softness.

Macroeconomic factors beyond the Fed decision have also weighed on crypto sentiment this week. Rising oil prices, driven by renewed hostilities between the United States and Iran, have added to broader inflation concerns across financial markets, a dynamic that traditionally creates headwinds for risk assets including cryptocurrencies. At the same time, a strengthening U.S. dollar has added further pressure, with analysts noting that the combination of higher oil prices and dollar strength has increased overall macro-volatility risk heading into the Fed’s announcement.

Trading data suggested bitcoin has largely oscillated within a defined range in recent sessions, generally trading between roughly $62,700 and $65,500. Some market analysts have pointed to that range as a key technical zone to watch in the near term, with the lower boundary near $62,700 serving as a support level and the $64,500 to $65,500 zone acting as resistance that bitcoin has struggled to convincingly break through in recent trading.

Advertisement

Beyond bitcoin and ether, individual cryptocurrency tokens showed more significant divergence Wednesday. Jupiter, a decentralized finance token, rose nearly 6% to lead gains within a broader recovery among DeFi-focused tokens, while artificial intelligence-linked tokens continued to struggle, with Fetch.ai falling more than 4% on the day as AI-related crypto tokens continued unwinding gains posted the previous month.

Bitcoin’s current price level remains well below its all-time highs reached earlier in the cryptocurrency’s price cycle, though the asset has still posted substantial gains compared with prior years, with its market capitalization standing at approximately $1.27 trillion to $1.33 trillion depending on the specific pricing snapshot used, maintaining its position as by far the largest cryptocurrency by market value, well ahead of ether’s market capitalization of roughly $233 billion.

With the Federal Reserve’s decision expected to be announced later Wednesday, crypto traders and analysts broadly expect increased volatility to follow the announcement, regardless of whether the central bank opts to raise rates, hold steady, or signal a different policy path than markets currently anticipate, given how closely digital asset prices have tracked broader shifts in monetary policy expectations throughout the past several weeks of trading.

Advertisement
Continue Reading

Business

Amazon Web Services India net profit jumps over 10-fold to Rs 242 cr in FY26

Published

on

Amazon Web Services India net profit jumps over 10-fold to Rs 242 cr in FY26
Amazon Web Services India Pvt Ltd has reported a more than 10-fold growth in consolidated net profit to Rs 242.8 crore in the financial year 2026, as per a document shared by market intelligence firm Tofler.

The cloud services arm of e-commerce giant Amazon had posted net profit of Rs 23.1 crore in FY25.

​Its consolidated revenue from operations grew by about 21 per cent to Rs 20,225.6 crore in FY26 from Rs 16,744.9 crore in FY25.

AWS, however, reported a decline of around 14 per cent in standalone net profit to Rs 242.4 crore in FY26, compared to Rs 281.5 crore in FY25.

Advertisement

The company’s revenue from operations on a standalone basis grew by 21.4 per cent to Rs 20,225.6 crore during the period under review from Rs 16,659 crore in the year-ago period.


“The company’s total expenses for the fiscal were reported at Rs 19,888 crore (on a standalone basis),” Tofler said.

Continue Reading

Business

Heathrow passengers to foot bill for third runway bidding process

Published

on

Business Live

The initial costs are expected to be recouped through ticket prices

a British Airways plane taking off from Heathrow Airport

A British Airways plane taking off from Heathrow Airport(Image: Daniel Leal-Olivas/PA Wire)

Heathrow will be allowed to pass the enormous bill it has accumulated in preparing its third runway bid on to passengers, the aviation watchdog has confirmed, in a ruling that looks set to cement the airport’s status as the costliest in the world.

The Civil Aviation Authority (CAA) ruled that Heathrow Airport Limited (HAL) will be entitled to recoup the £320m it has already spent competing to secure the megaproject contract by increasing the fees attached to travellers’ air fares.

Advertisement

Rival bidder Heathrow West was also granted permission to recover the £4.2m it has so far spent on its own proposal.

The two operators have been competing fiercely to persuade ministers to back their respective third runway plans, assembling extensive planning documents and feasibility studies, while also enlisting the services of expensive third-party advisers to bolster their bids.

For incumbent HAL, that investment has already stretched into the hundreds of millions, the CAA noted, with the hub previously arguing it needs to cover its early outlay if the expansion is to remain financially attractive, reports City AM.

In its ruling, the aviation regulator said without the design and planning efforts both bidders have undertaken to develop credible expansion proposals, the timely delivery of the third runway project would have been put at risk.

Advertisement

It added that both parties would need to demonstrate their claims had been independently scrutinised line by line before being permitted to pass on the costs.

“Our decision strikes a balance between supporting the delivery of benefits to consumers through timely progress on Heathrow expansion, whilst also protecting them from undue increases in costs,” said Tim Johnson, the UK Civil Aviation Authority’s director of consumers and markets.

“The costs Heathrow can recover are capped, independently scrutinised and subject to efficiency reviews, helping ensure that passengers only pay for efficient costs that are justified.”

Under the compensation scheme, agreed following a consultation held last year, HAL will be permitted to add 10p to every passenger fare over the next 20 to 25 years. It will also be responsible for recouping Heathrow West’s more modest costs, should the rival bid led by hotel magnate Surinder Arora fail to succeed.

Advertisement

The CAA reached its decision alongside a wide-ranging review of Heathrow’s overarching regulatory framework, in which it will determine whether rival operators will be permitted to own and run key infrastructure within the airport.

Airlines operating at the hub have grown increasingly frustrated with the exorbitant charges they are forced to pass on to passengers, and – in lockstep with Arora – some have established a pressure group lobbying for a wholesale shake-up of red tape at the airport.

At £28.80, the airport’s charges are already the costliest in the world, and are anticipated to climb by as much as £50 once the full expenditure of the third runway is factored in.

Wednesday’s CAA ruling will see the airport charge per passenger rise by approximately 15 pence in 2028, climbing to 30 pence in subsequent years.

Advertisement

The initial costs incurred by bidders are expected to be recouped through ticket prices over a period of roughly 20 to 25 years.

Continue Reading

Business

Automatic Data Processing, Inc. (ADP) Q4 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript